FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL 3235-

0104 Estimated average burden

OMB Number:

hours per response: 0.5

See footnotes<sup>(4)(5)</sup>

(6)(7)

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Date of Event 3. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person\* Requiring Statement (Month/Day/Year) Kinnate Biopharma Inc. [ KNTE ] ORBIMED ADVISORS LLC 12/02/2020 4. Relationship of Reporting Person(s) to 5. If Amendment, Date of Original (Last) (First) (Middle) Filed (Month/Day/Year) **601 LEXINGTON AVENUE** (Check all applicable) X 10% Owner Director 54TH FLOOR 6. Individual or Joint/Group Filing Officer (give Other (specify (Check Applicable Line) title below) below) Form filed by One Reporting (Street) Person **NEW** Form filed by More than One 10022 NY Reporting Person **YORK** (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities 3. Ownership 4. Nature of Indirect Beneficial Ownership (Instr. 5) Beneficially Owned (Instr. Form: Direct (D) or Indirect (I) (Instr. 5) Table II - Derivative Securities Reneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Direct (D) or Indirect (I) (Instr. 5)			
Series A Preferred Stock	(1)	(1)	Common Stock	293,995	(1)	I	See footnotes <sup>(2)(5)</sup> (6)(7)		
Series B Preferred Stock	(1)	(1)	Common Stock	2,660,503	(1)	I	See footnotes <sup>(3)(5)</sup> (6)(7)		

Common Stock

143,431

(1)

Name and Address of Reporting Person*     ORBIMED ADVISORS LLC						
(Last)	(First)	(Middle)				
601 LEXINGTON AVENUE						
54TH FLOOR						
(Street)						
NEW YORK	NY	10022				
(City)	(State)	(Zip)				
Name and Address of Reporting Person*     OrbiMed Capital GP VII LLC						
(Last)	(First)	(Middle)				
601 LEXINGTON AVENUE						
54TH FLOOR						
(Street)						
NEW YORK	NY	10022				

(1)

(1)

Series C Preferred Stock

(City)	(State)	(Zip)			
Name and Address of Reporting Person*     OrbiMed Genesis GP LLC					
(Last)	(First)	(Middle)			
601 LEXINGTON AVENUE					
54TH FLOOR					
(Street)					
NEW YORK	NY	10022			
(City)	(State)	(Zip)			

## **Explanation of Responses:**

- 1. Each share of the issuer's Series A Preferred Stock and Series B Preferred Stock will automatically convert into one share of common stock immediately prior to the completion of the issuer's initial public offering and has no expiration date. Each share of the issuer's Series C Preferred Stock will automatically convert into 1.00335008 shares of common stock immediately prior to the completion of the issuer's initial public offering and has no expiration date.
- 2. 243,494 of these shares are owned directly by OrbiMed Private Investments VII, LP (OPI VII); and 50,501 of these shares are held by OrbiMed Genesis Master Fund, L.P. (Genesis).
- 3. 2,651,042 of these shares are owned directly by OPI VII; and 9,461 of these shares are held by Genesis.
- 4. 118,794 of these shares are owned directly by OPI VII; and 24,637 of these shares are held by Genesis.
- 5. OrbiMed Capital GP VII LLC (OrbiMed GP VII) is the general partner of OPI VII and OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of OrbiMed GP VII. By virtue of such relationships, OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (Genesis GP) is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities.
- 6. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII and Genesis.
- 7. This report on Form 3 is jointly filed by OrbiMed Advisors, OrbiMed GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and OPI VII have designated a representative, Carl L. Gordon ("Gordon"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

## Remarks:

Date set forth above represents the effective date of the issuer's initial public offering.

OrbiMed Advisors LLC
By: /s/ Douglas Coon,
Chief Compliance Officer
OrbiMed Capital GP VII
LLC By: /s/ Douglas
Coon, Chief Compliance
Officer
OrbiMed Genesis GP, LLC
By: /s/ Douglas Coon,
Chief Compliance Officer
\*\* Signature of Reporting
Person
Dull 12/02/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.